- Report
- March 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Clinical Trials
- June 2024
- 60 Pages
Global
From €1365EUR$1,500USD£1,170GBP
- Report
- November 2023
- 30 Pages
Global
From €2503EUR$2,750USD£2,146GBP
- Report
- November 2023
- 30 Pages
Global
From €2503EUR$2,750USD£2,146GBP
- Report
- November 2023
- 630 Pages
Global
From €8646EUR$9,500USD£7,412GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
Pemetrexed is a chemotherapy drug used to treat non-small cell lung cancer (NSCLC). It is a type of antifolate, meaning it works by blocking the action of folic acid, which is essential for cancer cells to grow and divide. Pemetrexed is usually used in combination with other chemotherapy drugs, such as cisplatin or carboplatin. It is also used to treat mesothelioma, a type of cancer caused by exposure to asbestos.
Pemetrexed is approved by the US Food and Drug Administration (FDA) for the treatment of NSCLC and mesothelioma. It is available in both intravenous and oral formulations. The intravenous formulation is administered in combination with other chemotherapy drugs, while the oral formulation is used as a single agent.
Pemetrexed is marketed by several pharmaceutical companies, including Eli Lilly, Bristol-Myers Squibb, and Merck. It is also available as a generic drug in some countries. Show Less Read more